1. Home
  2. OVID vs PBYI Comparison

OVID vs PBYI Comparison

Compare OVID & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ovid Therapeutics Inc.

OVID

Ovid Therapeutics Inc.

HOLD

Current Price

$2.76

Market Cap

365.5M

Sector

Health Care

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$7.25

Market Cap

343.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OVID
PBYI
Founded
2014
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
365.5M
343.9M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
OVID
PBYI
Price
$2.76
$7.25
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$4.60
N/A
AVG Volume (30 Days)
4.6M
263.1K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
3.90
N/A
EPS
N/A
0.61
Revenue
$7,252,000.00
$27,685,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$22.53
N/A
P/E Ratio
N/A
$12.26
Revenue Growth
1181.27
N/A
52 Week Low
$0.27
$2.75
52 Week High
$3.11
$7.90

Technical Indicators

Market Signals
Indicator
OVID
PBYI
Relative Strength Index (RSI) 62.30 58.79
Support Level $1.31 $5.75
Resistance Level $3.11 N/A
Average True Range (ATR) 0.22 0.33
MACD 0.02 0.07
Stochastic Oscillator 67.74 66.38

Price Performance

Historical Comparison
OVID
PBYI

About OVID Ovid Therapeutics Inc.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: